Antibiotech
Antibiotech30About
What does Antibiotech do?
Antibiotech aims to revolutionize antibiotic treatment by providing bedside physicians with patient-specific, data-driven recommendations. Their digital health solution acts as a decision support system, leveraging advanced analytics to optimize antibiotic therapy.
What is Antibiotech's revenue?
StartupHub estimates Antibiotech's annual revenue at $543K (range $318K to $1.4M, 69% confidence), based on comparable companies in the sector.
Where is Antibiotech headquartered?
Antibiotech is headquartered in Tel Aviv, Israel.
When was Antibiotech founded?
Antibiotech was founded in 2019.
What industry does Antibiotech operate in?
Antibiotech operates in Healthcare, Digital Health, Decision Support, HealthTech, MedTech, AI-Driven Drug Discovery.
How many employees does Antibiotech have?
Antibiotech has approximately 3 people on record.
What is Antibiotech's current status?
Antibiotech's current operating status is: Inactive.
AI-powered platform for personalized weight management and health coaching.
Your health consultation for a pain-free life, offering pain management and therapy solutions.
AI-powered personalized sleep coaching and actionable insights for improving sleep quality.
AI-powered digital health platform offering personalized nutrition and wellness plans based on individual metabolism.
Longevity and metabolic health platform offering personalized insights and interventions.
Unifies personal health data into a single, user-controlled health record on your phone.
Improving NHS appointment access with a user-friendly digital solution.
A telehealth service offering convenient, 24/7 access to board-certified medical providers for urgent care and some specialty needs.
An entrant is a company tagged Digital Health whose domain was first registered in the window, counted from registry records in the StartupHub directory. 1 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.